ArticleBone marrow transplantation2025
Superior outcomes of haploidentical hematopoietic cell transplantation over chemotherapy in AML patients 55 years or older.
Article in Bone marrow transplantation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite advancements in treatment, the prognosis for elderly AML patients remains poor. We conducted a retrospective study involving 307 consecutive AML patients, including 71 who underwent haploidentical hematopoietic cell transplantation (Haplo) and 236 who received chemotherapy (Chemo) only. Propensity score matching with 1:1 ratio was performed to balance the groups based on age at treatment initiation, gender, and European Leukemia Net (ELN) 2022 risk classification. 69 case-controlled pairs in the Haplo and Chemo group were analyzed after matching. The two groups were comparable concerning therapy prior to complete remission and 72.5% of patients in the Haplo group received reduced-intensity conditioning. Haplo was associated with a significant survival advantage over Chemo, with a 1-year OS of 77.9% (95% confidence interval(CI), 65.5-86.3, p = 0.001) versus 62.0% (95% CI, 47.9-73.2, p = 0.009). A significanly higher 1-year LFS of 74.1% (95% CI, 61.5-83.1) was also observed compared with 42.0% (95% CI, 29.3-54.0) in the chemotherapy group (p < 0.0001). The survival advantage was majorly due to a significantly reduced relapse incidence (Haplo: 16.5% (95% CI, 8.7-26.5) vs Chemo: 56.6% (95% CI, 42.9-68.2)). The 1-year non-relapse mortality was 9.4% (95% CI, 3.8-18.2) in the Haplo group. To conclude, haploidentical HCT showed superior outcomes to chemotherapy alone and might be recommended to AML patients 55 years or older eligible for transplant in future practice.
Indexed as
Identifiers
40159557What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.